logo

Blueprint Medicines (BPMC)



Trade BPMC now with
  Date
  Headline
9/22/2020 7:05:06 AM Blueprint Medicines Announces Positive Top-line Results From EXPLORER And PATHFINDER Trials Of AYVAKIT
9/20/2020 11:51:41 AM Blueprint Medicines Reports ARROW Trial Data At ESMO Virtual Congress 2020
9/4/2020 8:01:44 AM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/1/2020 8:02:43 AM Blueprint Medicines Appoints Fouad Namouni As President, Research & Development
7/30/2020 7:23:35 AM Blueprint Medicines Q2 Net Loss $123.5 Mln Or $2.28/shr Vs. Net Loss $99.7 Mln Or $2.04/shr Last Year
7/24/2020 8:33:48 AM Blueprint Medicines Receives Positive CHMP Opinion For Avapritinib
7/14/2020 1:07:46 AM Blueprint Medicines Collaborates With Roche To Develop &Commercialize Pralsetinib For Patients With RET-Altered Cancers
7/14/2020 1:04:39 AM Roche, Blueprint Medicines Announce Signing Of Licensing And Collaboration Agreement
7/1/2020 8:13:58 AM Blueprint Medicines Submits NDA For Pralsetinib For Advanced RET Mutant And RET Fusion-Positive Thyroid Cancers
6/3/2020 8:07:24 AM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/29/2020 8:12:49 AM Blueprint Medicines Announces Data From Ongoing ARROW Clinical Trial Of Pralsetinib
5/15/2020 8:04:25 AM Blueprint Medicines Gets CRL From FDA For Avapritinib New Drug Application For Fourth-Line GIST